IAN T. CLARK - 17 Jun 2025 Form 4 Insider Report for Guardant Health, Inc. (GH)

Role
Director
Signature
/s/ John G. Saia, as attorney-in-fact for Ian T. Clark
Issuer symbol
GH
Transactions as of
17 Jun 2025
Transactions value $
-$322,819
Form type
4
Filing time
20 Jun 2025, 17:26:39 UTC
Previous filing
16 Jun 2025
Next filing
09 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
CLARK IAN T Director 3100 HANOVER STREET, PALO ALTO /s/ John G. Saia, as attorney-in-fact for Ian T. Clark 20 Jun 2025 0001336504

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GH Common Stock Sale -$323K -6.67K -40.38% $48.38 9.85K 17 Jun 2025 By The Thornton-Clark Family Trust, J Thornton-Clark & I Clark TTE Account F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GH Stock Option (Right to Buy) Award $0 +6.83K $0.00 6.83K 18 Jun 2025 Common Stock 6.83K $50.57 Direct F2
transaction GH Restricted Stock Units Award $0 +5.09K $0.00 5.09K 18 Jun 2025 Common Stock 5.09K $0.00 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.38 to $48.41 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The stock option vests in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier.
F3 The restricted stock units vest in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier.
F4 Not applicable for Restricted Stock Units.